Cargando…

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678898/ http://dx.doi.org/10.2147/NDT.S48159

Ejemplares similares

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
por: Kamijima, Kunitoshi, et al.
Publicado: (2013)

Sex differences in the prediction of the effectiveness of paroxetine for patients with major depressive disorder identified using a receiver operating characteristic curve analysis for early response [Corrigendum]
Publicado: (2014)

Corrigendum to ‘Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial’
por: von Rotz, Robin, et al.
Publicado: (2023)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

Milnacipran: recent findings in depression
por: Montgomery, Stuart, et al.
Publicado: (2010)

Short-Term Efficacy of Calcium Fructoborate on Subjects with Knee Discomfort: a Comparative, Double-Blind, Placebo-Controlled Clinical Study [Corrigendum]
Publicado: (2021)

Aloe sterol supplementation improves skin elasticity in Japanese men with sunlight-exposed skin: a 12-week double-blind, randomized controlled trial [Corrigendum]
Publicado: (2016)

Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study [Corrigendum]
Publicado: (2021)

Effect of high-dose milnacipran in patients with depression
por: Hayashi, Masatoshi, et al.
Publicado: (2007)

The Subjective and Objective Improvement of Non-Invasive Treatment of Schumann Resonance in Insomnia—A Randomized and Double-Blinded Study [Corrigendum]
Publicado: (2022)

Corrigendum to: A Multicenter, Prospective, Randomized, Placebo-Controlled, Double-Blind Study of a Novel Pain Management Device, AT-02, in Patients with Fibromyalgia
Publicado: (2020)

Corrigendum to “Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial”
por: Cheon, Chunhoo, et al.
Publicado: (2018)

Corrigendum to “Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study”
por: Faghihi, Gita, et al.
Publicado: (2017)

Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial
por: WANG, Zhiyang, et al.
Publicado: (2015)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
Publicado: (2015)

Corrigendum to “Local and Systemic Cardiovascular Effects from Monochromatic Infrared Therapy in Patients with Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Study”
por: Hsieh, Ru-Lan, et al.
Publicado: (2017)

Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
por: Hofmann, Peter
Publicado: (2010)

Use of milnacipran in patients suffering from poststroke depression
por: Arora, Harish, et al.
Publicado: (2009)

Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study
por: Pickering, Gisèle, et al.
Publicado: (2018)

Corrigendum to “High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study” [J Food Drug Anal 24 (2016) 866–875]
por: Achanti, Suneetha, et al.
Publicado: (2017)

Fibromyalgia, milnacipran and experimental pain modulation: study protocol for a double blind randomized controlled trial
por: Macian, Nicolas, et al.
Publicado: (2015)

Corrigendum to “Total Intravenous Anaesthesia with High-Dose Remifentanil Does Not Aggravate Postoperative Nausea and Vomiting and Pain, Compared with Low-Dose Remifentanil: A Double-Blind and Randomized Trial”
por: Kim, Seong-Hyop, et al.
Publicado: (2019)

Burden of comorbidities among Japanese patients with atrial fibrillation: a case study of dyspepsia [Corrigendum]
Publicado: (2013)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
Publicado: (2018)

Corrigendum: Protocol on transcranial alternating current stimulation for the treatment of major depressive disorder: a randomized controlled trial
Publicado: (2020)

Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial [Corrigendum]
Publicado: (2015)

Effect of a cod protein hydrolysate on postprandial glucose metabolism in healthy subjects: a double-blind cross-over trial — CORRIGENDUM
por: Dale, Hanna Fjeldheim, et al.
Publicado: (2019)

Corrigendum to: 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled tria
Publicado: (2020)

Corrigendum to “Influence of on emotions and behavior of adolescents with major depressive disorder” [Heliyon 9(5) (May 2023) e15890]
por: Lu, Heli, et al.
Publicado: (2023)

Effect of milnacipran on suicidality in patients with mild to moderate depressive disorder
por: Avedisova, Alla, et al.
Publicado: (2009)

Daily Intake of Kaempferia parviflora Extract Decreases Abdominal Fat in Overweight and Preobese Subjects: A Randomized, Double-Blind, Placebo-Controlled Clinical Study [Corrigendum]
Publicado: (2020)

Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice
por: Stasiuk, Weronika, et al.
Publicado: (2016)

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum]
Publicado: (2015)

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum]
Publicado: (2017)

Corrigendum to “Self-Reported Adverse Drug Reactions, Medication Adherence, and Clinical Outcomes among Major Depressive Disorder Patients in Ethiopia: A Prospective Hospital Based Study”
por: Abegaz, Tadesse Melaku, et al.
Publicado: (2018)

Plasma levels of interleukin-6 and 3-methoxy-4-hydroxyphenylglycol and treatment with milnacipran in major depression
por: Yoshimura, Reiji, et al.
Publicado: (2022)

Efficacy and Safety of a Subanesthetic Dose of Esketamine Combined with Propofol in Patients with Obesity Undergoing Painless Gastroscopy: A Prospective, Double-Blind, Randomized Controlled Trial [Corrigendum]
Publicado: (2023)

Corrigendum to “A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study”
por: Krishnareddy, Naveen T., et al.
Publicado: (2019)

Corrigendum: A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin Type A 150 kD Neurotoxin in the Cheek
por: Shin, Dong Min, et al.
Publicado: (2023)

Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan
por: Higuchi, Teruhiko, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_j0osvvpic0ocl3fudgvnk45730